Manufacturer of avatrombopag

Avatrombopag was developed by the American pharmaceutical company Dova Pharmaceuticals (later acquired by Sobi). Dova Pharmaceuticals is a biopharmaceutical company focused on rare diseases and hematology, committed to developing innovative treatment options to meet the needs of patients.

The company is committed to developing and promoting treatments for blood system diseases such as thrombocytopenia. Avatrombopag is one of the main R&D products of Dova Pharmaceuticals. It is developed to meet the treatment needs of patients with chronic immune thrombocytopenia (ITP).

Dova Pharmaceuticalshas invested significant time and resources in the development of avatrombopag. They conducted clinical trials to evaluate the safety and effectiveness of the drug and ultimately succeeded in obtaining approval from drug regulatory agencies for clinical use.

In 2018, Dova Pharmaceuticals was acquired by Sobi (Swedish Orphan Biovitrum AB) acquired Sobi, a Swedish-based biopharmaceutical company focused on developing and delivering medicines to treat rare diseases and specific chronic diseases.

Through this acquisition,Sobi will be able to further expand its product portfolio in rare diseases and hematology, strengthen its position in the global market, and will continue to support the development and promotion of drugs such as avatrombopag to provide more patients with the treatment options they need.

In summary, avatrombopag is manufactured byDova Pharmaceuticals (now Sobi) developed and produced by this biopharmaceutical company is one of the company's important achievements in the field of hematology, providing an effective treatment option for patients with thrombocytopenia such as ITP.